Your browser is no longer supported. Please, upgrade your browser.
Caribou Biosciences, Inc.
Index- P/E- EPS (ttm)- Insider Own6.70% Shs Outstand58.46M Perf Week-0.67%
Market Cap1.21B Forward P/E- EPS next Y-1.61 Insider Trans3.32% Shs Float54.27M Perf Month-21.86%
Income- PEG- EPS next Q-0.12 Inst Own23.90% Short Float3.04% Perf Quarter23.58%
Sales- P/S- EPS this Y-46.40% Inst Trans- Short Ratio1.84 Perf Half Y-
Book/sh- P/B- EPS next Y-33.10% ROA- Target Price30.67 Perf Year-
Cash/sh2.22 P/C9.34 EPS next 5Y2.30% ROE- 52W Range15.00 - 32.65 Perf YTD26.84%
Dividend- P/FCF- EPS past 5Y- ROI157.40% 52W High-33.70% Beta-
Dividend %- Quick Ratio5.50 Sales past 5Y- Gross Margin- 52W Low44.30% ATR1.68
Employees76 Current Ratio5.50 Sales Q/Q- Oper. Margin- RSI (14)48.07 Volatility5.64% 7.48%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.21 Prev Close20.70
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume898.02K Price21.65
Recom1.70 SMA200.14% SMA50-12.61% SMA200-8.31% Volume123,264 Change4.57%
Aug-17-21Initiated SVB Leerink Outperform $32
Aug-17-21Initiated Citigroup Neutral $27
Aug-17-21Initiated BofA Securities Buy $30
Oct-23-21 08:41AM  
Oct-22-21 07:50AM  
Oct-20-21 04:00PM  
Oct-14-21 11:25AM  
Sep-29-21 04:05PM  
Sep-27-21 04:05PM  
Sep-02-21 04:05PM  
Sep-01-21 08:00AM  
Aug-25-21 04:00PM  
Jul-27-21 04:05PM  
Jul-22-21 09:09PM  
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCCLUNG BARBARA GChief Legal OfficerOct 20Buy2.699,21924,799342,844Oct 21 06:12 PM
Kanner StevenChief Scientific OfficerOct 12Buy1.92114,860220,757215,031Oct 13 07:31 PM
Fischesser RyanVP of Finance and ControllerOct 11Buy2.691,7464,697100,559Oct 12 07:33 PM